Todd Garner to step down as CONMED’s CFO, effective March 15, 2026, and remain In an Advisory Role Through November 2, 2026 Company Initiates Comprehensive SearchTodd Garner to step down as CONMED’s CFO, effective March 15, 2026, and remain In an Advisory Role Through November 2, 2026 Company Initiates Comprehensive Search

CONMED Corporation Announces Chief Financial Officer Transition

2026/01/09 06:00
3분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

Todd Garner to step down as CONMED’s CFO, effective March 15, 2026, and remain In an Advisory Role Through November 2, 2026

Company Initiates Comprehensive Search for Next Chief Financial Officer

CONMED Reaffirms Full-Year 2025 Revenue and Adjusted EPS Outlook

LARGO, Fla.–(BUSINESS WIRE)–CONMED Corporation (NYSE: CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Mr. Garner will remain with the Company in an advisory capacity through November 2, 2026.

CONMED has initiated a comprehensive search process, supported by a leading executive search firm, to identify its next Chief Financial Officer.

“On behalf of our Board and leadership team, I want to thank Todd for his many contributions to CONMED over the past eight years,” said Pat Beyer, President and Chief Executive Officer. “Todd has been instrumental in strengthening our financial foundation and supporting strategic initiatives that position CONMED for scalable, long-term growth. We are also grateful for his commitment to ensuring a seamless transition.”

“I am grateful to my CONMED colleagues over the past eight years. It has been rewarding to be part of such a high-quality, driven team that has dramatically improved the revenue growth and profitability of the company. I’m committed to a smooth transition, positioning CONMED for strong future success,” said Todd Garner.

CONMED is reaffirming its full-year 2025 consolidated revenue and adjusted EPS guidance issued on November 5, 2025. Mr. Garner’s planned departure is not the result of any disagreement regarding the Company’s financial statements or disclosures.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company’s Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Contacts

CONMED Corporation
Pat Beyer
Chief Executive Officer
PatBeyer@conmed.com

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!